Fischer Adina S, Tapert Susan F, Lee Louie Dexter, Schatzberg Alan F, Singh Manpreet K
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA.
Department of Psychiatry, University of California San Diego, San Diego, CA.
Curr Treat Options Psychiatry. 2020 Jun;7(2):144-161. doi: 10.1007/s40501-020-00202-2. Epub 2020 Apr 18.
This review summarizes (1) recent trends in delta-9-tetrahydrocannabionol [THC] and cannabidiol (CBD) content in cannabis products, (2) neurobiological correlates of cannabis use on the developing adolescent brain, (3) effects of cannabis on psychiatric symptoms and daily functioning in youth (i.e., academic performance, cognition, sleep and driving), (4) cannabis products used to relieve or treat medical issues in youth, and (5) available treatments for cannabis use disorder in adolescence.
Despite marked increases in THC content and availability of cannabis, there has been a decline in perceived risk and an increase in use of THC extract products among youth in the United States. The primary psychiatric symptoms associated with cannabis use in youth are increased risk for addiction, depressive, and psychotic symptoms. Cannabis alters endocannabinoid system function which plays a central role in modulating the neurodevelopment of reward and stress systems. To date, few studies have examined neurobiological mechanisms underlying the psychiatric sequalae of cannabis exposure in youth. Adolescent cannabis exposure results in impaired cognition, sleep, and driving ability. There are very limited FDA-approved cannabinoid medications, none of them supporting their use for the treatment of psychiatric symptoms. Behavioral therapies are currently the mainstay of treating cannabis misuse, with no pharmacotherapies currently approved by the FDA for cannabis use disorder in youth.
Here, we summarize the most up-to-date knowledge on the neurobiological psychiatric, and daily function effects of the most commonly used cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). We then review FDA approved medical use of cannabinoid treatments as well as pharmacological and psychological treatments for cannabis use disorder in youth. Our current understanding of the effects of cannabis on the developing brain and treatments for cannabis misuse in youth remain limited. Future research aimed at examining the neurobiological effects of cannabis, with objective measures of exposure, over the course of pediatric development and in relation to psychiatric symptoms are needed.
本综述总结了以下内容:(1)大麻产品中Δ⁹-四氢大麻酚(THC)和大麻二酚(CBD)含量的近期趋势;(2)大麻使用对青少年发育中大脑的神经生物学关联;(3)大麻对青少年精神症状和日常功能的影响(即学业成绩、认知、睡眠和驾驶);(4)用于缓解或治疗青少年医学问题的大麻产品;(5)青少年大麻使用障碍的可用治疗方法。
尽管THC含量显著增加且大麻的可获得性提高,但美国青少年中对大麻的感知风险有所下降,THC提取物产品的使用有所增加。与青少年使用大麻相关的主要精神症状是成瘾、抑郁和精神病性症状的风险增加。大麻会改变内源性大麻素系统功能,该系统在调节奖赏和应激系统的神经发育中起核心作用。迄今为止,很少有研究探讨青少年接触大麻后精神后遗症的神经生物学机制。青少年接触大麻会导致认知、睡眠和驾驶能力受损。美国食品药品监督管理局(FDA)批准的大麻素药物非常有限,且均不支持将其用于治疗精神症状。行为疗法目前是治疗大麻滥用的主要方法,目前尚无FDA批准用于青少年大麻使用障碍的药物疗法。
在此,我们总结了关于最常用的大麻素Δ⁹-四氢大麻酚(THC)和大麻二酚(CBD)对神经生物学、精神状态和日常功能影响的最新知识。然后,我们回顾了FDA批准的大麻素治疗的医学用途以及青少年大麻使用障碍的药物和心理治疗方法。我们目前对大麻对发育中大脑的影响以及青少年大麻滥用治疗方法的理解仍然有限。需要开展未来研究,以客观的暴露测量方法,考察大麻在儿童发育过程中以及与精神症状相关的神经生物学影响。